The initial success of the copyright undeniably transformed the drug landscape, but investing in companies primarily reliant on unbranded versions presents a uncertain picture. Although early earnings were significant, the cessation of patents and the appearance of cheaper alternatives have weakened market share. Therefore, a thorough evaluation of